tiprankstipranks
Trending News
More News >

Phio Pharmaceuticals Reports Positive Phase 1b Trial Results

Story Highlights
  • Phio Pharmaceuticals announced positive results in its Phase 1b trial for INTASYL PH-762.
  • Two out of three patients achieved complete response, supporting PH-762 as a non-surgical alternative.
  • Looking for the best stocks to buy? Follow the recommendations of top-performing analysts.
Phio Pharmaceuticals Reports Positive Phase 1b Trial Results

Confident Investing Starts Here:

The latest update is out from Phio Pharmaceuticals ( (PHIO) ).

On May 7, 2025, Phio Pharmaceuticals announced positive pathology results from the third cohort of its ongoing Phase 1b clinical trial evaluating the safety and tolerability of INTASYL PH-762 for skin cancer treatment. Two out of three patients with cutaneous squamous cell carcinoma achieved complete pathologic response, indicating potential as a non-surgical alternative in the expanding skin cancer market. The trial, which has treated 10 patients to date, demonstrated no dose-limiting toxicities, supporting continued dose escalation and enrollment expected to complete in the third quarter of 2025.

Spark’s Take on PHIO Stock

According to Spark, TipRanks’ AI Analyst, PHIO is a Neutral.

Phio Pharmaceuticals is struggling financially, with no revenue and consistent losses, significantly impacting its stock score. The technical indicators show mixed signals, with some short-term momentum but bearish long-term trends. The valuation is speculative due to negative earnings. The recent board appointment is a positive corporate event but has limited impact on overall financial health.

To see Spark’s full report on PHIO stock, click here.

More about Phio Pharmaceuticals

Phio Pharmaceuticals Corp. is a clinical-stage siRNA biopharmaceutical company focused on developing immuno-oncology therapeutics using its proprietary INTASYL® gene silencing technology. The company aims to enhance the body’s immune cells to more effectively kill cancer cells, with its lead clinical program being PH-762, a compound that silences the PD-1 gene implicated in various forms of skin cancer.

Average Trading Volume: 3,027,482

Technical Sentiment Signal: Strong Sell

Current Market Cap: $8.22M

For detailed information about PHIO stock, go to TipRanks’ Stock Analysis page.

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.

Report an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1